Congress funds diabetes screening push to catch disease earlier
H.R. 9000 — SCREEN for Type 1 Diabetes Act of 2026 · Filed by Kim Schrier (D-WA) · 46 cosponsors · Introduced May 21, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the CDC to run a national public awareness campaign about Type 1 diabetes screening and early detection, including written materials, public service announcements across media, and grants to states and nonprofits to increase screening access in underserved communities. It authorizes $5 million per year through 2031 and requires a progress report to Congress within one year.
Why we flagged it
The bill's core function is straightforward: establish and fund a CDC-led national campaign to increase awareness and screening for Type 1 diabetes. It is a public health education and prevention measure with no hidden mechanisms or narrow beneficiaries.
What the text implies
- Increased screening rates may lead to earlier diagnosis, which could increase demand for insulin and diabetes management products and services, potentially benefiting pharmaceutical and medical device manufacturers.
- The bill's emphasis on culturally and linguistically competent resources may improve health equity by reaching communities with historically lower screening rates, though implementation success depends on grant recipient quality.
- Grants to nonprofits and state health departments create new funding streams for organizations working in diabetes awareness, potentially shifting resources within the public health ecosystem.
Who it affects
Ordinary people gain access to better information about early detection of a serious chronic disease, and underserved communities receive targeted resources to increase screening. There are no apparent costs to the public, and the campaign is designed to improve health outcomes through awareness and prevention.
Who stands to gain
- pharmaceutical companies (insulin manufacturers)
- medical device manufacturers (glucose monitors, pumps)
- nonprofit health organizations
- state and local public health departments
Named in the bill
CDC (Centers for Disease Control and Prevention), HHS (Department of Health and Human Services), National Academy of Medicine, State, local, and Tribal public health departments, Elementary and secondary schools, Institutions of higher education, Bristol Myers Squibb (BMY), Gilead Sciences (GH), Pfizer (PFE), DaVita (DVA), Johnson & Johnson (JNJ)
Where it stands
46 cosponsors: 38 Democrats, 8 Republicans.
- May 21, 2026 — Introduced · Congress.gov: “Introduced in House”
- May 21, 2026 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $220,000 in lobbying spend. A filing names 7 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 0% of bills with at least one filing.
Kim Schrier, the sponsor, reported $984,999 in PAC receipts in the 2026 cycle.
- Breakthrough T1d (formerly Known As Jdrf Intl.) — $220,000 on 1 filing
Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the full bill text on Jul 9, 2026; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Jun 2026 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-10-20.
“Congress funds diabetes screening push to catch disease earlier” QuorumCivic. https://share.quorumcivic.app/bill/119/hr9000 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.